One health therapeutics: Target-Based drug development for cryptosporidiosis and other apicomplexa diseases.

This is a review of the development of bumped-kinase inhibitors (BKIs) for the therapy of One Health parasitic apicomplexan diseases. Many apicomplexan infections are shared between humans and livestock, such as cryptosporidiosis and toxoplasmosis, as well as livestock only diseases such as neosporosis. We have demonstrated proof-of-concept for BKI therapy in livestock models of cryptosporidiosis (newborn calves infected with Cryptosporidium parvum), toxoplasmosis (pregnant sheep infected with Toxoplasma gondii), and neosporosis (pregnant sheep infected with Neospora caninum). We discuss the potential uses of BKIs for the treatment of diseases caused by apicomplexan parasites in animals and humans, and the improvements that need to be made to further develop BKIs. Copyright © 2020. Published by Elsevier B.V.

Citation

Wesley C Van Voorhis, Matthew A Hulverson, Ryan Choi, Wenlin Huang, Samuel L M Arnold, Deborah A Schaefer, Dana P Betzer, Rama S R Vidadala, Sangun Lee, Grant R Whitman, Lynn K Barrett, Dustin J Maly, Michael W Riggs, Erkang Fan, Thomas J Kennedy, Saul Tzipori, J Stone Doggett, Pablo Winzer, Nicoleta Anghel, Dennis Imhof, Joachim Müller, Andrew Hemphill, Ignacio Ferre, Roberto Sanchez-Sanchez, Luis Miguel Ortega-Mora, Kayode K Ojo. One health therapeutics: Target-Based drug development for cryptosporidiosis and other apicomplexa diseases. Veterinary parasitology. 2021 Jan;289:109336

Mesh Tags

Substances

PMID: 33418437

search → result